StockNews.AI
ABOS
StockNews.AI
152 days

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

1. Acumen Pharmaceuticals to report Q4 and year-end 2024 results on March 27. 2. Conference call scheduled for March 27 to discuss financial updates. 3. Ongoing Phase 2 trial for AβOs treatment shows promise after Phase 1 success. 4. Acumen focuses on Alzheimer’s disease with novel therapeutic candidate, ACU193.

Earnings
+1.69%Current Return
VS
-0.31%S&P 500
$1.1803/20 04:08 PM EDTEvent Start
$1.203/21 10:23 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results may enhance investor confidence, boosting stock value. Similar biotech companies have seen stock rallies following promising clinical updates.

How important is it?

The upcoming financial results and report on trial progress are crucial for investors.

Why Short Term?

The financial report and conference call may influence immediate trading behavior.

Related Companies

BIIBAMGNREGN
March 20, 2025 16:00 ET  | Source: Acumen Pharmaceuticals, Inc. NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.    The webcast audio will be available via this link. An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.  Investors: Alex Braunabraun@acumenpharm.com Media: AcumenPR@westwicke.com 

Related News